CRESCENT BIOPHARMA, INC. Sale of Stock, Consideration Received on Transaction
CRESCENT BIOPHARMA, INC. (CBIO) reported Sale of Stock, Consideration Received on Transaction of $22.45 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-04.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2017-03-01
- CRESCENT BIOPHARMA, INC. sale of stock, consideration received on transaction for the quarter ending 2016-09-30 was -$135.78K.
- CRESCENT BIOPHARMA, INC. sale of stock, consideration received on transaction for the quarter ending 2016-06-30 was $21.35M.
- CRESCENT BIOPHARMA, INC. sale of stock, consideration received on transaction for the quarter ending 2016-03-31 was $1.24M.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 9 month |
|---|---|---|---|---|---|
| 2016-09-30 | -$135.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $21.22M derived: sum of 2 quarters · filed 2016-11-04 | $22.45M 10-Q · filed 2016-11-04 | ||
| 2016-06-30 | $19.70M 10-K · filed 2017-03-01 | $21.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $22.59M 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | $1.24M 10-Q · filed 2016-05-04 | ||||
| 2016-03-28 | $1.10M 10-Q · filed 2016-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |